Recalbon tablets 1mg or Bonoteo tablets 1mg (Minodronic acid hydrate) is an orally taken bisphosphonate that was first discovered in Japan and reportedly exhibits extremely potent inhibition of bone resorption in the class. It is said to be the first drug that demonstrated significant effect in prevention of bone fractures superior to placebo in Japanese osteoporosis patients in Phase III double blind comparative study.
The drug, once approved, can reportedly contribute to the improvement of the patients’ quality of life by offering an additional therapeutic option for the treatment of osteoporosis.
The drug will be available under the trade name of Recalbon tablets 1mg by Ono and Bonoteo tablets 1mg by Astellas respectively.